Autopsy report · NCT00424840
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
Cause of deathSlow enrollment
“Poor accrual”
Life of this trial
- Registered 7 months after it had already started.
- Ran for about 7 years 9 months before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 4 years 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- University of Massachusetts, Worcester
- Sponsor type
- University, hospital or other
- Conditions
- Lung Cancer
- Interventions
- Bortezomib 1.3 mg/m2; Bortezomib 1.6 mg/m2; Bortezomib 1.8 mg/m2; Carboplatin AUC 6; Bevacizumab; Taxotere
- Participants
- 12
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.